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Abstract
Neuregulin-1 (NRG-1) is reported to be cardioprotective through the extracellular-reg-
ulated protein kinase (ERK) 1/2 pathway in myocardial ischaemia-reperfusion injury 
(MIRI). NOX4-induced ROS activated NLRP3 inflammasome and exacerbates MIRI. 
This study aims to investigate whether NRG-1 can suppress NOX4 by ERK1/2 and 
consequently inhibit the NLRP3/caspase-1 signal in MIRI. The myocardial infarct size 
(IS) was measured by TTC-Evans blue staining. Immunohistochemical staining, real-
time quantitative PCR (RT-qPCR) and Western blotting were used for detection of 
the factors, such as NOX4, ERK1/2, NLRP3, caspase-1 and IL-1β .The IS in the NRG-1 
(3 μg/kg, intravenous) group was lower than that in the IR group. Immunohistochemical 
analysis revealed NRG-1 decreased 4HNE and NOX4. The RT-qPCR and Western blot 
analyses revealed that NRG-1 mitigated the IR-induced up-regulation of NOX4 and 
ROS production. Compared with the IR group, the NRG-1 group exhibited a higher 
level of P-ERK1/2 and a lower level of NLRP3. In the Langendorff model, PD98059 in-
hibited ERK1/2 and up-regulated the expression of NOX4, NLRP3, caspase-1 and IL-1β, 
which exacerbated oxidative stress and inflammation. In conclusion, NRG-1 can reduce 
ROS production by inhibiting NOX4 through ERK1/2 and inhibit the NLRP3/caspase-1 
pathway to attenuate myocardial oxidative damage and inflammation in MIRI.
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1  | INTRODUC TION
Various studies have reported that inflammasomes are involved in the 
pathophysiology of myocardial ischaemia-reperfusion injury (MIRI).1 
Recently, NLRP3 inflammasome was demonstrated to be up-regu-
lated in MIRI.2 Reactive oxygen species (ROS) stimulate inflammasome 
during the pathogenesis of MIRI.1 All known NLRP3 activators gen-
erate ROS, whereas the inhibitors of ROS suppress inflammasome 
activation.3-5 NADPH oxidase (NOX) 4-mediated ROS production pro-
motes NLRP3 inflammasome activation.6,7 Additionally, NOX4, which 
is the major ROS synthesis enzyme in the cardiac tissue, plays an im-
portant role in the cardiomyocytes.8 The inhibition of NOX4 activity 
can down-regulate ROS production and alleviate MIRI.9
Neuregulin-1 (NRG-1), a member of the epidermal growth fac-
tor family,10 is expressed in Coronary microvascular endothelial cells 
(CMEC) and exerts a paracrine effect. Additionally, NRG-1 is involved 
in the regulation of cardiac development 11 and adult cardiac func-
tion.12 Erythroblastic leukaemia viral oncogene homolog 4 (ErbB4), 
a tyrosine kinase receptor of NRG-1, dimerizes with ErbB2 or ErbB4 
upon activation by NRG-1 11 and consequently activates the down-
stream signalling pathways. NRG-1 is reported to exert an antioxi-
dant effect in the myocardial tissue and cells through the activation 
of the AKT/eNOS pathway.13-15 Previously, we had demonstrated 
that NRG-1 could suppress apoptosis through ERK1/2 activation in 
myocardial reperfusion injury.16 In other models, ERK1/2 activation 
can suppress NOX4, which leads to the down-regulation of ROS pro-
duction.17 Currently, there are no studies that have examined the 
ability of NRG-1 to suppress NOX4 and down-regulate ROS pro-
duction through ERK1/2 activation. In this study, we demonstrated 
that NRG-1 exerts antioxidant effects by suppressing NOX4 in a rat 
MIRI model and a Langendorff MIRI model. Additionally, this study 
demonstrated that the NRG-1-mediated suppression of NOX4 is de-
pendent on the activation of ERK1/2.
The role of NRG-1 in mitigating inflammatory damage in ce-
rebral ischaemia-reperfusion (IR) injury has been previously 
reported.18 However, there are limited studies on the anti-inflam-
matory effects of NRG-1 in the myocardial tissue. In septic cardio-
myopathy models, NRG-1 can inhibit NLRP3 inflammasome.6 As 
NRG-1 down-regulated ROS production by inhibiting NOX4, this 
study also examined the ability of NRG-1 to inhibit the NLRP3/
caspase-1 signalling pathway.
2  | MATERIAL S AND METHODS
2.1 | Animals
Male adult Sprague-Dawley rats weighing 300-350g (6-8 weeks 
old)were purchased from the Laboratory Animal Center of Peking 
University. We followed the Principles of Laboratory Animal Care 
(NIH publication no. 85-23, revised 1996), and all the animal ex-
perimental procedure was approved by the Animal Care Committee, 
Peking University Health Science Center.
2.2 | Assessment of MIRI in vivo
2.2.1 | MIRI model
According to previous protocols,19,20 rats were anaesthetized 
by sodium pentobarbital (50 mg/kg) through intraperitoneal in-
jection. and then a rodent respirator (ALCV9A; Shanghai Alcott 
Biotech Co., Ltd., Shanghai, China) was used for ventilation. The 
heart was exposed by a left thoracotomy through the 4th or 5th 
intercostal space. After the pericardium was removed, the left 
coronary artery (LCA) was occluded beneath the left atrial ap-
pendage by a 6-0 silk suture for 45 minutes. Ischaemia was con-
firmed by the myocardium blanching, ventricular dyskinesia and 
elevation of ST segment on the ECG. The heart was then reper-
fused for 24 hours by untying the knot, and reperfusion was con-
firmed by a marked hyperaemic response.21
2.2.2 | In vivo experimental protocol
The rats were divided into three groups randomly: (1) CON (con-
trol, n = 12) group, in which a left thoracotomy was done without 
occlusion of LCA; (2) IR (ischaemia reperfusion, n = 20, motality 
40%,12 rats were used for the followed experiments) group, in 
which 45 minutes were for LCA occlusion and 24 hours were for 
reperfusion; (3) IR + NRG-1 (n = 18, motality 33%,12 rats were 
used for the followed experiments) group, in which the LCA oc-
clusion lasted for 45 minutes, and just before 24 hours’ reperfu-
sion, recombinant human NRG-1β2 (rhNRG-1β2, 3 μg/kg, Prospec, 
Israel) was injected via the jugular vein intravenously(Figure 1B). 
The dosage of NRG-1 in this study was based on our previous 
study.16
2.3 | MIRI model in Langendorff apparatus
2.3.1 | Heart preparation
According to a previous protocol,22 we anaesthetized the rats 
by sodium pentobarbital (50 mg/kg) and removed the heart to a 
Langendorff apparatus. The heart was then perfused through the 
aorta retrogradely with the Krebs-Henseleit (K-H) buffer (NaCl 
118.5 mM, KCl 4.7 mM, KH2PO4 1.2 mM, NaHCO3 25.0 mM, MgSO4 
1.2 mM, glucose 11 mM and CaCl2 2.5 mM, at pH 7.4 and gassed 
with 95% O2 and 5% CO2 at 37°C). The heart was equilibrated for 
20 minutes at 70 mmHg.
2.3.2 | Isolated heart experimental protocol
The rats were divided to four groups randomly(n = 12): (a) CON 
(no-intervention) group; (b) IR group, in which the coronary flow 
was blocked for 30 minutes, and then, the heart was reperfused 
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for 2hrs; (c) NRG-1(IR + NRG-1) group, in which 20 ng/mL NRG-1 
(the dosage of NRG-1 was according to our previous study16) was 
perfused for 20 minutes; (d) NRG-1 + PD(IR + NRG-1 + PD98
059, an inhibitor of ERK1/2) group, in which the treatment was 
similar to the NRG-1 group, but 20 μM PD98059 (the dosage of 
PD was determined according to a previous study16) was perfused 
for 10 minutes before the reperfusion and lasted for 20 min at 
the reperfusion period. After the ischaemia period, all the hearts 
were reperfused for 2hrs and then were collected for the followed 
experiments(Figure 5C).
F I G U R E  1   NRG-1 protects against myocardial ischaemia-reperfusion injury. A, Representative cardiac tissue sections stained with 
Evans blue and triphenyl tetrazolium chloride [blue, non-ischaemic area; non-blue, area at risk (AR); white, infarct size (IS)]. B, The in 
vivo experiment protocol. C, The ratio of IS/AR. (D) Serum creatinine kinase-MB concentration. E, Representative paraffin-embedded 
cardiac sections subjected to immunohistochemical staining to detect 4-hydroxynonenal (4HNE) at the risk area. The cellular nuclei are 
shown in blue, whereas 4HNE-positive areas are shown in brown. F, Representative M-mode echocardiograms for each group, with (G) EF; 
H, FS quantified in bar graphs. Data are represented as mean ± standard error of mean (n = 6; *P < .05 vs. IR, #P < .05 vs. CON). CON, sham-
operated control; IR, ischaemia-reperfusion; NRG-1, IR + NRG-1
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2.4 | Assessment of infarct size
The staining was performed according to a previous protocol.23 At 
the end of the reperfusion in vivo, we ligated LCA again and infused 
the heart with Evans blue (Sigma, St. Louis, MO, USA, 0.25% in sa-
line) from the aorta retrogradely. The non-ischaemic part of ventri-
cle was stained blue, the non-stained part represented the area at 
risk (AR, non-blue region). When the heart was frozen for 30 min-
utes at − 20°C, the heart was segmented into 6 slices of 2 mm thick-
ness. The heart slices were incubated in 1% triphenyltetrazolium 
chloride (TTC, Sigma, St, Louis, MO, USA) in phosphate buffer (pH 
7.4) for 10 min at 37°C and then immersed in 4% paraformaldehyde 
for 24 hours. Infarct Size (IS, white region) was differentiated by TTC 
staining from the non-infarct AR (red region).In the experiment in 
vitro, the rat heart slices were single stained by TTC without Evans 
blue according to a previous protocol.22The red region indicated the 
non-infarct area of the left ventricle (LV). Finally, the slices were ar-
ranged from base to apex and photographed digitally. Digital images 
of the heart slices were analysed by ImageJ software (NIH, USA) to 
measure the IS and AR region. The result is presented as IS/AR% 
for experiment in vivo. And in Langendorff experiment, the result is 
presented as IS/LV% according to a previous study.21
2.5 | Western blotting
When the rat was sacrificed, the risk area of the LV was frozen by 
liquid nitrogen and then stored at −80°C. Frozen heart tissues for 
protein extraction were homogenized in RIPA solution. As previ-
ously described, 80 μg extracted protein was used for SDS-PAGE 
and immunoblotting.24ECL chemiluminescence was performed by an 
imaging system (molecular imager, ChemiDoc XRS, Bio-Rad, USA).
And the bands density were detected by the same software. All pro-
tein levels were standardized to GAPDH. Primary antibodies in the 
present study were as follows: T-ERK1/2, 202Thr/204Tyr-P-ERK1/2, 
NLRP3, GPX1, caspase-1 and IL-1β (rabbit monoclonal antibodies, Cell 
Signaling Technology, USA); GAPDH (mouse anti-human monoclonal 
antibody, Millipore, USA); NRG-1 and NOX4 (rabbit polyclonal anti-
bodies, Abcam, USA) and appropriate horseradish peroxidase(HRP)-
conjugated secondary antibody (ZSGB-BIO, China).
2.6 | Immunohistochemistry
Tissue sections were deparaffinized and then blocked with CAS-
Block (Invitrogen, CA) for 1 h. Incubated the sections with primary 
antibody (NOX4, 4HNE, CD31; Abcam, USA) for 2h at 37°C followed 
by incubation with secondary antibody linked with HRP for 1 h at 
37°C. Place sections in solution for DAB reaction for 3min. At last, 
sections were then stained with haematoxylin for 2 min, washed with 
PBS, and mounted with mounting medium (Abcam, USA). Capillary 
density was assessed based on the capillary/myocyte nucleus (C/M) 
values as previously described.25
2.7 | RNA isolation and quantitative real-time PCR
The total RNA of heart tissues was isolated using Trizol reagent 
(Invitrogen, USA). And a RT kit (Invitrogen, USA) was used for the 
production of the first-strand cDNA. 35 cycles were designated for 
amplifications in the Mx3000 Multiplex Quantitative PCR System 
(Stratagene, USA) with SYBR green fluorescence (Molecular Probes, 
Eugene, USA). Each cycle included heating denaturation for 30 sec-
onds at 94°C, annealing for 30 s at 56°C and extension for 30 sec-
onds at 72°C. Relative quantitation of gene expression normalized to 
GAPDH of all the samples were quantitated by the comparative CT 
method as previously described.21 The primers in this experiment 
were as follows: NOX4, forward TGGCCAACGAAGGGGTTAAA and 
reverse CACTGAGAAGTTCAGGGCGT; GPX1, forward CAGTCC 
ACCGTGTATGCCTT and reverse GTAAAGAGCGGGTGAGCCTT;
CAT, forward TTTTCACCGACGAGATGGCA and reverse AAGGT 
GTGTGAGCCATAGCC.
2.8 | DHE staining
ROS production in left ventricular myocardium in vitro was de-
termined by dihydroethidium (DHE, Invitrogen Molecular Probes, 
Eugene, USA) staining. Briefly, transverse cryosections (6μm thick) 
of frozen hearts were fixed with acetone for 15 minutes and then 
washed with 0.01%PBS 3 times before the incubation of DHE (5 μM) 
for 30min at room temperature. DHE fluorescence was assessed by 
a fluorescence microscopy.
2.9 | TUNEL assay and immunofluorescence
The harvested hearts were fixed with 4% paraformaldehyde and em-
bedded in paraffin. Heart sections were mounted on glass slides and 
then deparaffinized/hydrated for TUNEL staining. TUNEL staining 
was performed following the manufacturer's protocol in situ cell death 
detection kit (Roche Applied Science).Sections were also colabelled 
with primary antibody against cardiac α-sarcomeric actin antibody 
(1:50; Bioss) for 1 hour at 37°C in a humidified chamber to determine 
presence of apoptosis in cardiac myocytes. Sections were washed 
and incubated with secondary antibody, and the heart sections were 
counterstained with DAPI to stain all nuclei present in the heart sec-
tion. Sections were then examined with a confocal microscope.
2.10 | Creatine kinase-MB detection
At 24 h post-reperfusion, the blood samples were collected and then 
centrifuged at 2000rpm for 10 min at 4˚C. CK-MB (E006-1-1) levels 
in serum were detected according to the manufacturer's protocols 
(Nanjing Jiancheng Bioengineering Institute). The optical density of 
the tetrazolium product was determined spectrophotometrically 
(Molecular Devices, LLC) at a wavelength of 490 nm.
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2.11 | Echocardiography
At 24 hours post-reperfusion, echocardiography was performed on 
rats anesthetized with sodium pentobarbital (25 mg/kg) as described 
previously26 (15). Measurements were obtained from short axis 
M-mode images and graphically represented as EF% (left ventricular 
ejection fraction) and FS% (left ventricular fraction shortening).
2.12 | Statistical analysis
All data are shown as the mean ± SEM. Statistical comparisons among the 
groups were performed using one-way ANOVA followed by Neuman-
Keuls post hoc test or Tukey's post hoc test. The statistical analyses 
were accomplished by GraphPad Prism 8.0 (Graph Pad Software, San 
Diego, CA). A value of P ≤ .05 was considered statistically significant.
3  | RESULTS
3.1 | Protective effects of NRG-1 in vivo
At 24 hours post-reperfusion, Evans blue staining and TTC staining 
were performed to examine the IS and AR (Figure 1A). The IS/AR ratio 
was used as an indicator of myocardial injury.21 Treatment with NRG-1 
significantly decreased the IS value (Figure 1C; P < .05). Compared 
with those in the sham group, the serum CK-MB levels were higher in 
the IR group and lower in the NRG-1 group (Figure 1D; P < .05). The 
levels of 4-hydroxynonenal (4HNE), which is the final product of lipid 
oxidation, are associated with the severity of oxidative damage.27 
Immunohistochemical analysis revealed that the 4HNE level was mark-
edly up-regulated in the IR group (Figure 1E). However, the 4HNE levels 
in the NRG-1 group were lower than those in the IR group (Figure 1E). 
The IR group resulted in a significant reduction in EF% (Figure 1G, 
P< .05) and FS% (Figure 1H, P < .05). No significant differences of EF% 
and FS% were found between the IR group and NRG-1group(Figure 1F-
H).The capillary density in the IR group was significantly lower than that 
in the CON group (Figure 2A; P < .05). No significant differences were 
found between the IR group and NRG-1 group (Figure 2A). Apoptosis 
in the IR group was significantly higher than that in the CON group 
(Figure 2B–C; P < .001). Treatment with NRG-1 significantly mitigated 
apoptosis induced by myocardial reperfusion (Figure 2B; P < .01).
3.2 | NRG-1 down-regulates the expression of 
NOX4 in vivo
NOX4 plays an important role in regulating the ROS levels in the myocar-
dial tissue.28 The mRNA expression levels of Nox4 were up-regulated in 
the IR group (Figure 3A). Treatment with NRG-1 significantly mitigated 
the IR-induced up-regulated mRNA levels of Nox4 (Figure 3A; P < .05). 
Additionally, the expression levels of the antioxidant genes Cat and Gpx-1 
were also examined. IR did not affect the mRNA levels of Gpx-1. In contrast, 
treatment with NRG-1 significantly up-regulated the mRNA levels of 
Gpx-1 (Figure 3B, P< .01). The mRNA levels of Cat were not significantly 
different among the three groups (Figure 3C). Immunohistochemical 
analysis revealed that the level of NOX4 was markedly up-regulated in 
the IR group (Figure 3D). The level of NOX4 in the NRG-1 group was 
markedly lower than that in the IR group (Figure 3D).
3.3 | NRG-1 reduced the expression of NOX4 
via the activation of ERK1/2
Phosphorylation of ERK1/2 (44 kDa/42 kDa) is reported to play a 
critical role in the downstream signals of NRG-1/ErbB4.11 Compared 
with that in the IR group, the ERK1/2 phosphorylation level was 
higher in the NRG-1 group (Figure 3E and G, P < .05). The effect of 
NRG-1 on the expression levels of NOX4 and GPX-1 was examined 
using Western blotting. The expression level of NOX4 in the IR group 
was significantly higher than that in the CON group. Treatment with 
NRG-1 significantly mitigated the IR-induced up-regulated NOX4 
levels (Figure 3E and F; P < .01). NRG-1 markedly increased the 
mRNA levels of Gpx-1. However, the levels of GPX-1 were not signifi-
cantly different among the three groups (Figure 3E and H; P > .05).
3.4 | NRG-1 suppressed the NLRP3/
caspase-1 pathway
The cardioprotective effect of NRG-1 was evaluated by examin-
ing the expression of proteins involved in the NLRP3/caspase-1 
pathway using Western blotting. Compared with that in the CON 
group, the expression of NLRP3(110 kDa) was up-regulated in the 
IR group (Figure 4A-B; P < .01). Treatment with NRG-1 significantly 
mitigated the IR-induced up-regulated levels of NLRP3 (Figure 4A-
B; P < .05). The expression levels of pro-caspase-1 (48 kDa) and 
its activated fragment cleaved caspase-1 (20 kDa) were determined 
using Western blotting (Figure 4A). Compared with that in the CON 
group, the level of cleaved caspase-1 was significantly up-regulated 
in the IR group (Figure 4C; P < .05). The expression level of cleaved 
caspase-1 in the NRG-1 group was lower than that in the IR group 
(Figure 4C; P < .05). However, the protein levels of pro-caspase-1 
were not significantly different among the three groups.IL-1β, the 
downstream factor of caspase-1, was up-regulated in the IR group 
at protein level compared with that in the CON group(Figure 4C; 
P < .05). Treatment with NRG-1 significantly mitigated the NLRP3-
induced up-regulated levels of IL-1β (Figure 4A and D; P < .05).
3.5 | PD98059 (PD) inhibited the protective 
effect of rhNRG-1 in vitro
To determine the role of ERK1/2 activation in mediating the antiox-
idant effect of NRG-1, PD (a MEK inhibitor) was used to inhibit the 
phosphorylation of ERK1/2 in the Langendorff IR model. Treatment 
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with PD inhibited the protective effect of NRG-1. The IS value in 
the NRG-1 + PD group was higher than that in the NRG-1 group 
(Figure 5A–B, P < .01). The results of the DHE assay revealed that IR 
increased ROS production, which was markedly inhibited upon treat-
ment with NRG-1 (Figure 5D). Treatment with PD inhibited the anti-
oxidant effect of NRG-1 and consequently enhanced ROS production 
(Figure 5D). The TUNEL assay was also performed to examine apopto-
sis in the Langendorff model. The percentage of TUNEL-positive cells 
in the NRG-1 group was significantly lower than that in the IR group 
(Figure 6A and B; P < .01). Compared with that in the NRG-1 group, 
the percentage of TUNEL-positive cells was significantly higher in the 
NRG-1 + PD group (Figure 6A and B ; P < .05).
F I G U R E  2   NRG-1 shows no effect on myocardial capillary density but mitigates myocardial apoptosis. A, Immunohistochemical analysis 
of CD31 was performed to evaluate the myocardial capillary density. Capillary density was assessed based on the capillary/myocyte nucleus 
(C/M) values. Magnification: 200X. The CD31+ capillary endothelial cells are shown in brown. Myocardial sections were counterstained with 
haematoxylin (nuclei are stained blue). B, The percentage of terminal deoxynucleotidyl transferase dUTP nick end labelling (TUNEL)-positive 
cells among the total number of cells. C, Representative myocardial sections subjected to the TUNEL assay. TUNEL-positive cells are shown 
in green. The 4′,6-diamidino-2-phenylindole (DAPI)-stained nuclei are shown in blue. The cardiomyocytes stained with anti-α-SCA antibody 
are shown in red. Data are represented as mean ± standard error (n = 6; *P < .05 vs CON; ***P < .001 vs. CON; ##P < .01 vs IR). CON, sham-
operated control; IR, ischaemia-reperfusion; NRG-1, IR + NRG-1
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3.6 | PD up-regulates the expression of NOX4 and 
NLRP3/caspase-1 pathway in vitro
To examine the role of ERK1/2 activation in mediating NRG-1-induced 
suppression of NOX4 , PD was used to block the phosphorylation of 
ERK1/2 in the Langendorff IR model. Treatment with PD markedly 
inhibited the NRG-1-induced phosphorylation of ERK1/2 (Figure 7A 
and C). Additionally, the expression level of NOX4 in the NRG-1 
group was significantly lower than that in the IR group. Treatment 
with PD significantly up-regulated the levels of NOX4 (Figure 7A and 
F I G U R E  3   NRG-1 down-regulates the expression of NOX4 by activating ERK1/2. The mRNA expression levels of Nox4 (A), Gpx-
1 (B), and Cat (C) were detected using quantitative real-time polymerase chain reaction. (D) Representative paraffin-embedded 
cardiac sections subjected to immunohistochemical staining to detect NOX4 at the risk area. The cellular nuclei are shown in blue, whereas 
NOX4-positive areas are shown in brown. E. Representative Western blots showing the levels of NOX4, P-ERK1/2, T-ERK1/2, GPX-1 and 
GAPDH. Semi-quantification of NOX4 level (F), the P-ERK1/2 density/T-ERK1/2 density ratio (G), and GPX-1 level (H). The expression levels 
of target proteins were normalized to those of GAPDH Data are represented as mean ± standard error of mean (n = 6; *P < .05, **P < .001 
vs. IR). CON, sham-operated control; IR, ischaemia-reperfusion; NRG-1, IR + NRG-1
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B; P < .05). The expression of NLRP3, a downstream signal of NOX4, 
was examined as it is reported to be down-regulated by NRG-1 in 
vivo. In the Langendorff model, NRG-1 could suppress the expres-
sion of NLRP3 (Figure 6 A and D, P < .01), which was mitigated upon 
treatment with PD (Figure 6 A andD,P < .05). For downstream fac-
tors, the expression levels of pro-caspase-1, cleaved caspase-1 and 
IL-1β were determined using Western blotting (Figure 7A). The ex-
pression level of cleaved caspase-1 in the NRG-1 group was lower 
than that in the IR group (Figure 7E, P < .01). When treated with 
PD, the cleaved caspase-1 was significantly up-regulated compared 
with the NRG-1 group(Figure 7E, P < .05). The protein levels of pro-
caspase-1 were not significantly different among the four groups.
IL-1β, the downstream factor of caspase-1, was down-regulated 
in the NRG-1 group at protein level compared with that in the IR 
group(Figure 7F; P < .01). Treatment with PD significantly up-regu-
lated the levels of IL-1β (Figure 7A and F; P < .05).
4  | DISCUSSION
Previously, we had demonstrated that NRG-1 can down-regulate ap-
optosis in cardiomyocytes through the RISK pathway.16 Additionally, 
NRG-1 is reported to exert an anti-inflammatory effect in the 
brain tissue.18 Furthermore, NRG-1 can reduce myocardial oxida-
tive damage by regulating eNOS activity.29 In this study, NRG-1 
decreased ROS production through novel pathways and alleviated 
inflammation-induced damage. This indicated that NRG-1 can de-
crease ROS production by inhibiting NOX4 through ERK1/2 activa-
tion and consequently exert protective effects on the myocardial 
tissue by inhibiting the NLRP3/caspase-1 pathway.
To define the cardioprotective effects of NRG-1, we detected 
the myocardial apoptosis by a TUNEL assay, and α-SCA immuno-
fluorescence staining was performed to specify the cardiomyo-
cytes. In the present study, we found that NRG-1 can significantly 
alleviate apoptosis of myocardial sections both in vivo and in vit-
ro(Figures 2 and 6), which is consistent to previous work.16,30 To 
determine the myocardial injury, plasma CK-MB was detected. 
In NRG-1 group the concentration of CK-MB was lower than 
that in IR group, indicating the cardioprotective effects of NRG-
1(Figure 1D).To determine the effect of NRG-1 on cardiac func-
tion, echocardiogram was used to assess the cardiac function. In 
IR group, the EF% and FS% are both deceased compared with the 
CON group. This result is consistent to a previous study.26How-
ever, no significant differences were found between the IR group 
and NRG-1 group(Figure 1F-H).This result indicated that the cardi-
oprotection of NRG-1 did not rely on the improvement of cardiac 
function, and its anti-apoptosis and antioxidant effect will play 
more important roles in the mechanism of cardioprotection. A pre-
vious study showed that long-term treatment with NRG-1 would 
improve cardiac function of the ischaemic heart via anti-remodel-
ling effects.26In our experiment, only a bolus of NRG-1(3 μg/kg) in-
jected intravenously at the onset of reperfusion was not sufficient 
F I G U R E  4   NRG-1 suppresses 
the NLRP3/caspase-1 pathway. A. 
Representative Western blots showing 
the levels of NLRP3, caspase-1, cleaved 
caspase-1, IL-1β and GAPDH. Semi-
quantification of NLRP3 level (B), the 
cleaved caspase-1 density/caspase-1 
density ratio (C), and IL-1β level (D). The 
expression levels of the target proteins 
were normalized to those of GAPDH. 
Data are represented as mean ± standard 
error of mean (n = 6; *P < .05,**P < .001 
vs CON; #P < .05 vs. IR). CON, sham-
operated control; IR, ischaemia-
reperfusion; NRG-1, IR + NRG-1
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to improve cardiac function. We only used EF% and FS% to assess 
the effect of NRG-1 on systolic function, the influence of NRG-1 
on the diastolic function in MIRI rats would be examined in the 
future.
The production of ROS, which is up-regulated during MIRI, may 
damage the myocardial tissue through various pathways, including 
degradation of various structural proteins and enzymes, DNA dam-
age, calcium overload and induction of cardiomyocyte apoptosis.31 
The levels of 4HNE, which is the product of lipid peroxidation, indi-
cate the levels of ROS production. DHE staining can also determine 
the content of ROS in the cardiomyocytes. In this study, treatment 
with NRG-1 decreased the content of 4HNE in the rat model of MIRI 
(Figure 1D) and the fluorescence intensity of DHE in the Langendorff 
model. This indicated that NRG-1 exerts anti-inflammatory effects 
(Figure 5C).
Previous studies have demonstrated that GPX-1 and CAT are 
involved in the regulation of ROS clearance in the cardiomyo-
cytes.32 To evaluate the effect of NRG-1 on ROS clearance, the ef-
fect of NRG-1 on the expression of GPX-1 and CAT was examined. 
Treatment with NRG-1 significantly up-regulated the mRNA ex-
pression level of Gpx-1 but not that of Cat (Figure 2B–C). Therefore, 
we speculate that NRG-1 may clear ROS through GPX-1. However, 
F I G U R E  5   PD98059 mitigates the NRG-1-mediated alleviation of myocardial injury. A. Triphenyl tetrazolium chloride (TTC) staining was 
used to detect the infarct size. Representative cardiac sections stained with TTC (red, ischaemic area; white, infarct area). B. The percentage 
of infarct size/left ventricle (IS/LV%). C. The Langendorff experiment protocol. D. Representative frozen cardiac sections subjected to 
dihydroethidium(DHE) staining to detect reactive oxygen species at the risk area. Data are represented as mean ± standard error of mean 
(n = 6; **P < .01 vs IR; ##P < .01 vs. NRG-1). CON, sham-operated control; IR, ischaemia-reperfusion; NRG-1, IR + NRG-1; PD, PD98059
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treatment with NRG-1 did not affect the expression level of GPX-1 
(Figure 3A and D). There is no evidence for the NRG-1-mediated 
clearance of ROS through GPX-1, which must be examined in future 
studies.
The production of intracellular ROS is mediated mainly through 
NADPH oxidase and the mitochondrial pathway. Recent studies 
have reported that NOX2 and NOX4, which are the main sources 
of cardiac ROS, play a vital role in the growth and death of cardio-
myocytes.28,33 The cardiac tissue-specific knockout of Nox4 exac-
erbates MIRI.34 In this study, the effect of NRG-1 on the expression 
of NOX4 was examined. NRG-1 down-regulated the mRNA expres-
sion of Nox4. This suggested that the antioxidant effect of NRG-1 
F I G U R E  6   PD98059 increases the number of terminal deoxynucleotidyl transferase dUTP nick end labelling (TUNEL)-positive cells. 
(A) Representative myocardial sections subjected to the TUNEL assay. TUNEL-positive cells are shown in green. The 4′,6-diamidino-2-
phenylindole (DAPI)-stained nuclei are shown in blue. The α-SCA-positive cardiomyocytes are shown in red. (B) The percentage of TUNEL-
positive cells among the total number of cells. Data are represented as mean ± standard error of mean (n = 6; **P < .01 vs IR; #P < .05 
vs. NRG-1). CON, sham-operated control; IR, ischaemia-reperfusion; NRG-1, IR + NRG-1; PD, PD98059
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is mediated through the inhibition of NOX4, which leads to the 
down-regulation of ROS synthesis. Western blotting and immuno-
histochemical analyses revealed that NRG-1 significantly down-reg-
ulated the expression of NOX4 (Figures 2D and 3A). This further 
confirms that NRG-1 down-regulates ROS synthesis by inhibiting 
NOX4. A previous study found that inhibiting NOX4 may aggravate 
endothelium dysfunction.35In chronically overloaded heart, myo-
cardial NOX4 preserves capillary density.36 In the present study, 
we found that the myocardial capillary density in IR group is lower 
than that in the CON group which is consistent to a previous study37 
(Figure 3). But no significant differences were found between the 
IR group and NRG-1group (Figure 3).This results demonstrated that 
a bolus injection of NRG-1 was not sufficient to affect the capillary 
density. Whether the effects of NRG-1 on capillary density was re-
lated to the expression of NOX4 remains unknown and more work 
should be done in the future.
In our previous work, we had proved that the cardioprotec-
tive effect of NRG-1 was dependent on the activation of ErbB4 
and the downstream signal ERK1/2.16It has been reported that 
ErbB2 and ErbB4 are expressed in adult rat hearts and ErbB3 is 
expressed in neonatal rat hearts.11But a recent study showed that 
postconditioning may affect the ROS production and regulate the 
expression of ErbB3 in MIRI model.38This inferred that in our 
experiment, the ErbB3 may be involved with antioxidant effect 
of NRG-1. And the relationship between ErbB3 and NOX4, even 
the NLRP3/caspase-1 signal, will be a promising field to explore 
further.
Next, the upstream and downstream mechanisms of NOX4 
regulation were examined. Previous studies have demonstrated 
that NRG-1 can activate the ERK1/2 pathway.11 The activation of 
the ERK1/2 pathway is reported to down-regulate the expression 
of NOX4,17 which results in decreased ROS production. Previously, 
we had demonstrated that the administration of NRG-1 can signifi-
cantly activate ERK1/2 in the MIRI model.16 In this study, we demon-
strated the negative correlation between NRG-1 administration and 
NOX4 expression. Thus, we hypothesized that the inhibitory effect 
of NRG-1 on NOX4 expression in the MIRI model depends on the 
activation of the ERK1/2 pathway. To verify this hypothesis, an 
ERK1/2 inhibitor (PD98059) was used to verify the correlation be-
tween ERK1/2 and NOX4 in the Langendorff model. Treatment with 
F I G U R E  7   PD98059 up-regulates 
the expression of NOX4 and NLRP3/
caspase-1 pathway. A, Representative 
Western blots showing the levels of 
NOX4, P-ERK1/2, T-ERK1/2, caspase-1, 
NLRP-3, cleaved caspase-1, IL-1β and 
GAPDH. Semi-quantification of NOX4 
level (B), the P-ERK1/2 density/T-ERK1/2 
density ratio (C), NLRP3 level (D), the 
cleaved caspase-1 density/caspase-1 
density ratio (C) and IL-1β level (E). The 
expression levels of target proteins 
were normalized to those of GAPDH. G. 
A proposed schematic diagram of the 
molecular pathway activated by NRG-1. 
Data are represented as mean ± standard 
error of mean (n = 6; *P < .05 vs IR; 
##P < .001 vs. NRG-1). CON, sham-
operated control; IR, ischaemia-
reperfusion; NRG-1, IR + NRG-1; PD, 
PD98059
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PD98059 blocked ERK1/2 and up-regulated NOX4 expression. This 
indicated that PD98059 significantly mitigated the NRG-1-mediated 
down-regulation of NOX4. These findings suggest that NRG-1 inhib-
its NOX4 by activating ERK1/2 and consequently down-regulating 
ROS production.
Enhanced levels of ROS can promote cardiomyocyte apop-
tosis.28 Previously, we had reported that NRG-1 can inhibit car-
diomyocyte apoptosis. In addition to promoting cardiomyocyte 
apoptosis, ROS can damage cardiomyocytes by activating the 
NLRP3 inflammasome. Inflammation injury also plays an important 
role in MIRI.39 Previous studies have reported the anti-inflamma-
tory effect of NRG-1 in cerebral IR injury.40 The anti-inflammatory 
effect of NRG-1 in myocardial tissues has not been explored. As 
NRG-1 down-regulated ROS synthesis in this study, we focused 
on ROS-mediated NLRP3 activation. Treatment with NRG-1 sig-
nificantly down-regulated the expression of Nlrp3 in vivo and the 
expression of caspase-1 and IL-1β (Figures 4 and 7). This indicated 
that NRG-1 exerts myocardial protective effects by down-regulat-
ing NLRP3/caspase-1 signalling pathway.
The upstream and downstream mechanisms of ERK1/2 and 
NLRP3 were clarified by examining the expression of NLRP3 in the 
Langendorff model. Treatment with PD98059 up-regulated the 
expression of NLRP3, cleaved caspase-1 and IL-1β(Figure 7). This 
suggested that the expression of NLRP3 is dependent on the NRG-
1-mediated activation of ERK1/2. The results of this study and pre-
vious studies suggest that the activity of NLRP3 is associated with 
NOX4-mediated ROS production.
Above all, we conclude that NRG-1 reduces ROS synthesis by 
inhibiting NOX4 through ERK1/2, inhibits NLRP3 inflammasome and 
ultimately plays a role in myocardial protection.
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